Indi Molecular Inks PCC Development Deal with Sigma, But Main Focus Now on Therapeutics | GenomeWeb

NEW YORK (GenomeWeb) – Indi Molecular this week announced a co-development deal with Sigma-Aldrich to explore use of its PCC (protein catalyzed capture) agent technology in Sigma-Aldrich's line of protein research reagents.

Despite the deal, though, Indi Molecular has shifted its focus from developing PCCs as research and diagnostic tools to therapeutics, CEO Albert Luderer told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.